CDK9 and neoplasm: Most selective CDK9 inhibitors, such as AZD4573, atuveciclib, VIP152, A-1592668 and JSH-150, have been shown to reduce tumor growth, mainly in hematological malignancies, in vitro and in vivo, and some of them have already progressed to phase I clinical trials (Table 1).